Paper Details

  1. Home
  2. Paper Details

[Long-term follow-up of chronic hepatitis C after treatment with recombinant interferon alpha-2a].

Author: BauditzJ, BergT, HeuftH, HopfU, HuhnD, KönigV, KütherS, LobeckH, SoltaniK

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study investigated the effectiveness of interferon alfa-2a treatment for chronic hepatitis C infection. After two months of treatment, 42% of patients had normalized liver enzymes, while 73% tested negative for HCV RNA. These rates decreased over time, with 23% normalized liver enzymes and 35% negative HCV RNA after 3 years. However, patients who maintained remission remained HCV RNA negative. Increasing the dosage of interferon did not improve response rates. Antibodies to interferon developed in 10% of patients but did not significantly affect treatment effectiveness. Liver biopsies showed improvement in 61% of patients, including all those with normalized liver enzymes. The study suggests that a lack of improvement in liver enzymes within the first two months may indicate a poor response to treatment. Sustained normalization of liver enzymes and negative HCV RNA after one year suggest a maintained remission.
Paper Details　
Original Abstract of the Article :
As part of a multicenter randomized study 40 patients with chronic hepatitis C (HCV)-infection, 28 kryptogenic and 12 posttransfusional, were treated with recombinant interferon alfa (IFN alpha-2a) for 1 year in a dosage of 3 x 3 Mio. units per week versus dosis escalation after 8 and 16 weeks in se...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/7975783

データ提供：米国国立医学図書館（NLM）

Long-Term Follow-Up of Chronic Hepatitis C After Treatment with Recombinant Interferon Alpha-2a

This study delves into the challenging world of chronic hepatitis C (HCV) infection. The researchers, like explorers in a vast desert, are investigating the long-term effects of recombinant interferon alpha-2a, a drug used to treat HCV, on patients’ health. They conducted a long-term follow-up study to evaluate the sustained effects of interferon alpha-2a treatment on HCV infection. The results revealed that while a significant number of patients initially responded well to treatment, the long-term remission rates were lower. The authors also found that the response to treatment varied, highlighting the need for individualised approaches to managing HCV infection.

A Shifting Landscape: Managing Chronic Hepatitis C

This long-term follow-up study provides valuable insights into the challenges of managing chronic hepatitis C. The authors found that while interferon alpha-2a treatment resulted in significant initial responses, the long-term remission rates were lower. This highlights the need for continued monitoring and potential adjustments to treatment plans to achieve sustained remission in HCV-infected patients.

Navigating the HCV Desert: Finding a Sustainable Path to Recovery

This study underscores the importance of understanding the long-term implications of treatment for chronic HCV infection. The authors emphasize the need for continued monitoring and potentially adjusted treatment plans to achieve sustained remission, which are essential for improving the long-term health of HCV-infected patients.

Dr.Camel's Conclusion

This study highlights the long-term challenges associated with chronic hepatitis C infection and the need for individualized treatment strategies to achieve sustainable remission. It's like navigating a vast desert, reminding us that managing HCV requires a careful and persistent approach to guide patients towards a healthier future.

Date :
  1. Date Completed 1994-12-08
  2. Date Revised 2018-11-30
Further Info :

Pubmed ID

7975783

DOI: Digital Object Identifier

7975783

Related Literature

Article Analysis
・Effective treatment of hepatitis c
SNS
PICO Info
in preparation
Languages

German

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.